40587-07-3

Upstream product

• 99-90-1 para-bromoacetophenone 
• 74-89-5 methylamine 
• 32017-76-8 (+/-)-2-(4-bromophenyl)oxirane 
• 1431664-66-2 C₁₀H₁₂BrNO 
• 1122-91-4 4-bromo-benzaldehyde 

Downstream Products

• 885595-75-5 tert-butyl 2-(4-bromophenyl)-2-(4-chlorophenyl)ethyl(methyl)carbamate 
• 885595-50-6 (2-(4-bromophenyl)-2-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-phenyl]-ethyl)-methyl-carbamic acid tert-butyl ester 
• 942057-59-2 tert-butyl 2-(4-chlorophenyl)-2-(4-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)phenyl)ethyl(methyl)carbamate 
• 857531-36-3 2-(4-bromophenyl)-2-(4-chlorophenyl)-N-methylethanamine 
• 566949-43-7 [2-(4-bromo-phenyl)-2-hydroxy-ethyl]-methyl-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

A simple two-step synthesis of 2-(alkylamino)-1-arylethanols, including racemic adrenaline, from aromatic aldehydes via 5-aryloxazolidines

Benzaldehydes react smoothly with nonstabilized azomethine ylides, generated in situ from sarcosine/formaldehyde or N-(methoxymethyl)-N- (trimethylsilylmethyl)benzylamine, to give 5-aryloxazolidines as intermediates. These were converted into 2-(alkylamino)-1-arylethanols in good yields by simple heating in methanol with hydrochloric acid, or by treatment with hydrazine hydrate in ethanol.

PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS

The invention provides a combination comprising an ancillary compound (e.g. one, two or more ancillary compounds) and a compound of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing f

PHARMACEUTICAL COMPOUNDS

The invention provides compounds of the formula (I) having ROCK kinase and/or protein kinase p70S6K inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length

Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof

The invention relates to sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones compounds having formula (I) wherein R1 is selected from the group consisting of 4-methylsulfonyl, 4-aminosulfonyl, hydrogen, 2-, 3-, or 4-halogen, C1-C6